Cargando…

Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study

BACKGROUND: Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose lowering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinedion...

Descripción completa

Detalles Bibliográficos
Autores principales: Adua, Eric, Roberts, Peter, Sakyi, Samuel Asamoah, Yeboah, Francis Agyemang, Dompreh, Albert, Frimpong, Kwasi, Anto, Enoch Odame, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587509/
https://www.ncbi.nlm.nih.gov/pubmed/28879491
http://dx.doi.org/10.1186/s40169-017-0162-5
_version_ 1783261996268912640
author Adua, Eric
Roberts, Peter
Sakyi, Samuel Asamoah
Yeboah, Francis Agyemang
Dompreh, Albert
Frimpong, Kwasi
Anto, Enoch Odame
Wang, Wei
author_facet Adua, Eric
Roberts, Peter
Sakyi, Samuel Asamoah
Yeboah, Francis Agyemang
Dompreh, Albert
Frimpong, Kwasi
Anto, Enoch Odame
Wang, Wei
author_sort Adua, Eric
collection PubMed
description BACKGROUND: Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose lowering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinediones (TNZ)], lipid lowering (statins), and anti-hypertensive medicines [angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin II receptor blockers (ARBs) and central acting drugs (CADs)] have been approved for controlling hyperglycaemia, dyslipidaemia and hypertension respectively. Here, we examined factors that characterise T2DM and explored the response to medication therapy among T2DM patients. METHODS: This prospective cohort study recruited 241 T2DM patients reporting at a clinic in Ghana, from January through to August, 2016. Each patient’s demographic, medications and anthropometric data was obtained while information on medication adherence was captured using Morisky adherence scale-8 (MMAS-8). Fasting blood samples were collected for biochemical analysis. RESULTS: The mean age of participants was 57.82 years for baseline and six-month follow-up. Physical activity differed at baseline and follow up (p < 0.05) but not body mass index (BMI). BIG alone, or in combination with SUA and TNZ did not improve glycaemic status at follow up (p > 0.05). Many participants using either ACEI or ARB were able to control their blood pressures. Among dyslipidaemia patients under statin treatment, there was an improved lipid profile at follow-up. CONCLUSIONS: Statin medications are effective for reducing dyslipidaemia in T2DM patients. However, control of modifiable risk factors, particularly blood glucose and to a lesser degree blood pressure is suboptimal. Addressing these will require concomitant interventions including education on medication adherence and correct dietary plans, lifestyle modifications and physical activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40169-017-0162-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5587509
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-55875092017-09-27 Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study Adua, Eric Roberts, Peter Sakyi, Samuel Asamoah Yeboah, Francis Agyemang Dompreh, Albert Frimpong, Kwasi Anto, Enoch Odame Wang, Wei Clin Transl Med Research BACKGROUND: Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose lowering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinediones (TNZ)], lipid lowering (statins), and anti-hypertensive medicines [angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin II receptor blockers (ARBs) and central acting drugs (CADs)] have been approved for controlling hyperglycaemia, dyslipidaemia and hypertension respectively. Here, we examined factors that characterise T2DM and explored the response to medication therapy among T2DM patients. METHODS: This prospective cohort study recruited 241 T2DM patients reporting at a clinic in Ghana, from January through to August, 2016. Each patient’s demographic, medications and anthropometric data was obtained while information on medication adherence was captured using Morisky adherence scale-8 (MMAS-8). Fasting blood samples were collected for biochemical analysis. RESULTS: The mean age of participants was 57.82 years for baseline and six-month follow-up. Physical activity differed at baseline and follow up (p < 0.05) but not body mass index (BMI). BIG alone, or in combination with SUA and TNZ did not improve glycaemic status at follow up (p > 0.05). Many participants using either ACEI or ARB were able to control their blood pressures. Among dyslipidaemia patients under statin treatment, there was an improved lipid profile at follow-up. CONCLUSIONS: Statin medications are effective for reducing dyslipidaemia in T2DM patients. However, control of modifiable risk factors, particularly blood glucose and to a lesser degree blood pressure is suboptimal. Addressing these will require concomitant interventions including education on medication adherence and correct dietary plans, lifestyle modifications and physical activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40169-017-0162-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-09-07 /pmc/articles/PMC5587509/ /pubmed/28879491 http://dx.doi.org/10.1186/s40169-017-0162-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Adua, Eric
Roberts, Peter
Sakyi, Samuel Asamoah
Yeboah, Francis Agyemang
Dompreh, Albert
Frimpong, Kwasi
Anto, Enoch Odame
Wang, Wei
Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study
title Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study
title_full Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study
title_fullStr Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study
title_full_unstemmed Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study
title_short Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study
title_sort profiling of cardio-metabolic risk factors and medication utilisation among type ii diabetes patients in ghana: a prospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587509/
https://www.ncbi.nlm.nih.gov/pubmed/28879491
http://dx.doi.org/10.1186/s40169-017-0162-5
work_keys_str_mv AT aduaeric profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy
AT robertspeter profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy
AT sakyisamuelasamoah profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy
AT yeboahfrancisagyemang profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy
AT domprehalbert profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy
AT frimpongkwasi profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy
AT antoenochodame profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy
AT wangwei profilingofcardiometabolicriskfactorsandmedicationutilisationamongtypeiidiabetespatientsinghanaaprospectivecohortstudy